PSD psivida limited

uk approval for brachysil pancreatic trial

  1. fluffynymph
    56,911 Posts.
    lightbulb Created with Sketch. 288
    clock Created with Sketch.
    30/05/06
    11:44
    Post #: 1593566
    Sydney - Tuesday - May 30: (RWE Aust Business News) - PSivida
    (ASX:PSD) has received approval from the regulatory agency of the United
    Kingdom for the the first human study of BrachySil in pancreatic cancer
    through a phase 11a clinical trial.
    Pancreatic cancer is a second clinical indication for BrachySil,
    which is currently in a Phase 11b clinical trial for the treatment of
    inoperable primary liver cancer.
    Pancreatic cancer has one of the lowest survival rates of cancers
    and there is significant demand for effective therapies to treat it.
    PSD Price at posting: 0.0¢ Sentiment: Buy Disclosure: Not Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Gold producers Alkane and Mandalay make merger official
right-arrow Created with Sketch.
AII Building assets, producing critical minerals and slashing dependency on China
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.